Breaking Finance News

Zacks Investment Research disclosed Merck & Co., Inc. (NYSE:MRK), boosting its price target to $70.00 earlier today

Reporting a potential upside of 0.12%, Zacks Investment Research upped the price target of Merck & Co., Inc. (NYSE:MRK) to $70.00

Boasting a price of $62.51, Merck & Co., Inc. (NYSE:MRK) traded -0.59% lower on the day. With the last stock price close up 5.98% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Merck & Co., Inc. has recorded a 50-day average of $62.57 and a two hundred day average of $58.63. Volume of trade was up over the average, with 12,204,208 shares of MRK changing hands over the typical 10,050,800

Performance Chart

Merck & Co., Inc. (NYSE:MRK)

With a total market value of $0, Merck & Co., Inc. has price-earnings ratio of 34.09 with a one year low of $47.97 and a one year high of $64.86 .

A total of 20 equity analysts have released a ratings update on MRK. Two equity analysts rating the company a strong buy, seven equity analysts rating the company a buy, thirteen equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $61.60.

Brief Synopsis About Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *